The rationale behind using mRNA level to dichotomise our cases instead of the patient outcome is that at this low level of protein expression, HER2 is not the driver oncogene and the clinical behaviour of the tumour and outcome is typically not dependent upon activation of the HER2 pathways.31, 40. This evidence concerns the gene ERBB2 and neoplasm.